Updates are available Correction dated 2022-04-21
Click to view Correction: https://doi.org/10.1038/s41591-022-01817-z
-
Authors
August, Allison https://orcid.org/0000-0002-8668-5252
Attarwala, Husain Z.
Himansu, Sunny https://orcid.org/0000-0002-7954-9674
Kalidindi, Shiva
Lu, Sophia
Pajon, Rolando
Han, Shu
Lecerf, Jean-Michel
Tomassini, Joanne E.
Hard, Marjie
Ptaszek, Leon M. https://orcid.org/0000-0003-1344-4471
Crowe, James E. https://orcid.org/0000-0002-0049-1079
Zaks, Tal
-
Funding
Funding for this research was provided by:
Moderna Therapeutics, Cambridge Massachusetts, USA
- License Information
-
More Information
Article History
Received: 5 March 2021
Accepted: 6 October 2021
First Online: 9 December 2021
Change Date: 21 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-022-01817-z
Competing interests
: J.E.C. has served as a consultant for Luna Biologics, is a member of the Scientific Advisory Boards of Meissa Vaccines and is founder of IDBiologics. The Crowe laboratory at Vanderbilt University Medical Center has received sponsored research agreements from IDBiologics and AstraZeneca. L.M.P. is a consultant for Abbott, Broadview Ventures, Bristol Myers Squibb, Moderna, Pfizer and WorldCare Clinical. A.A., H.Z.A., S.Himansu, S.K., S.L., R.P., S.Han, J.-M.L. and T.Z. are employees of, and M.H. is a former employee of, Moderna and may hold stock/stock options in the company. J.E.T. is a consultant of Moderna.
